m-PEG-NHS ester (MW 40000) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects[1].

m-PEG-NHS ester (MW 40000) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects[1].

m-PEG-NHS ester (MW 40000) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects[1].

m-PEG-NHS ester (MW 40000) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects[1].

M1AP Human Pre-designed siRNA Set A contains three designed siRNAs for M1AP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

M3554 is a novel anti-GD2 ADC designed based on humanized ch14.18 anti-GD2 antibody and has anti-tumor activity. The cytotoxicity of M3554 against the GD2-positive neuroblastoma cell line CHP134 was in the subnanomolar IC50 range.

M40 TFA is the TFA salt form of M40. M40 TFA is an antagonist or a weak agonist for galanin receptor depending on different subtypes of galanin receptors in the brain, hypothalamus, hippocampus, amygdala and pancreas[1][2][3].

M4K2281 is a selecitve inhibitor for activin receptor-like kinase-2 (ALK2) with an IC50 of 2 nM. M4K2281 exhibits a moderate blood brain permeability with a brain to plasma ratio of 3.7 at 4h[1].

M4K2306 is a selective inhibitor for activin receptor-like kinase-2 (ALK2) with an IC50 of 7 nM. M4K2306 is blood brain permeable with a brain to plasma ratio of 75.6[1].

M65 TFA is a deleted peptide of maxadilan (61 a.a.) with deletion of the residues between positions 24 and 42 and is a specific antagonist of PACAP type 1 receptor that inhibits ANP secretion and can be used for relevant researches[1][2].

M65 TFA is a deleted peptide of maxadilan (61 a.a.) with deletion of the residues between positions 24 and 42 and is a specific antagonist of PACAP type 1 receptor that inhibits ANP secretion and can be used for relevant researches[1][2].

M65 TFA is a deleted peptide of maxadilan (61 a.a.) with deletion of the residues between positions 24 and 42 and is a specific antagonist of PACAP type 1 receptor that inhibits ANP secretion and can be used for relevant researches[1][2].

M6PR Human Pre-designed siRNA Set A contains three designed siRNAs for M6PR gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MAB21L1 Human Pre-designed siRNA Set A contains three designed siRNAs for MAB21L1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MAB21L2 Human Pre-designed siRNA Set A contains three designed siRNAs for MAB21L2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MAB21L3 Human Pre-designed siRNA Set A contains three designed siRNAs for MAB21L3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Mabuterol hydrochloride is a selective and orally active beta-2 adrenergic receptor (ADRB2) agonist. Mabuterol hydrochloride inhibits the proliferation and suppresses the increase of intracellular Ca2+ induced by PDGF-BB. Mabuterol hydrochloride suppresses the protein expressions of Drp-1, cyclinD1 and PCNA and enhanced the expression of Mfn-2 induced by PDGF-BB[1][2].

MACC1 Human Pre-designed siRNA Set A contains three designed siRNAs for MACC1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MACF1 Human Pre-designed siRNA Set A contains three designed siRNAs for MACF1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MACIR Human Pre-designed siRNA Set A contains three designed siRNAs for MACIR gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MACO1 Human Pre-designed siRNA Set A contains three designed siRNAs for MACO1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MACROD1 Human Pre-designed siRNA Set A contains three designed siRNAs for MACROD1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MACROD2 Human Pre-designed siRNA Set A contains three designed siRNAs for MACROD2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MACROH2A1 Human Pre-designed siRNA Set A contains three designed siRNAs for MACROH2A1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MAD1L1 Human Pre-designed siRNA Set A contains three designed siRNAs for MAD1L1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MAD2L1 Human Pre-designed siRNA Set A contains three designed siRNAs for MAD2L1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MAD2L1BP Human Pre-designed siRNA Set A contains three designed siRNAs for MAD2L1BP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MAD2L2 Human Pre-designed siRNA Set A contains three designed siRNAs for MAD2L2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MADCAM1 Human Pre-designed siRNA Set A contains three designed siRNAs for MADCAM1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MADD Human Pre-designed siRNA Set A contains three designed siRNAs for MADD gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MAEA Human Pre-designed siRNA Set A contains three designed siRNAs for MAEA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MAEL Human Pre-designed siRNA Set A contains three designed siRNAs for MAEL gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MAF Human Pre-designed siRNA Set A contains three designed siRNAs for MAF gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MAF1 Human Pre-designed siRNA Set A contains three designed siRNAs for MAF1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MAFA Human Pre-designed siRNA Set A contains three designed siRNAs for MAFA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MAFB Human Pre-designed siRNA Set A contains three designed siRNAs for MAFB gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MAFF Human Pre-designed siRNA Set A contains three designed siRNAs for MAFF gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MAFG Human Pre-designed siRNA Set A contains three designed siRNAs for MAFG gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MAFK Human Pre-designed siRNA Set A contains three designed siRNAs for MAFK gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MAG Human Pre-designed siRNA Set A contains three designed siRNAs for MAG gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MAGE-1 nonapeptide (MAGE-1 (161-169), human) is a radioiodinated photoreactive derivative from MAGE-1 encoded melanoma tumor antigen[1].

MAGE-3 peptide (MAGE-3 168-176, human) is a peptide encoded by human MAGE-3 gene, which is expressed in tumor cells, presented by HLA and recognized by cytolytic T lymphocytes (CTL) as tumor antigen[1].